Compare MURA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MURA | VNRX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | MURA | VNRX |
|---|---|---|
| Price | $2.03 | $0.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.00 | $3.17 |
| AVG Volume (30 Days) | 224.8K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $0.95 | $0.27 |
| 52 Week High | $4.74 | $0.94 |
| Indicator | MURA | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 31.94 |
| Support Level | $2.06 | $0.28 |
| Resistance Level | $2.10 | $0.31 |
| Average True Range (ATR) | 0.01 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.00 | 3.40 |
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.